Obsidian Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Obsidian Therapeutics's estimated annual revenue is currently $19.2M per year.
- Obsidian Therapeutics's estimated revenue per employee is $155,000
- Obsidian Therapeutics's total funding is $325M.
Employee Data
- Obsidian Therapeutics has 124 Employees.
- Obsidian Therapeutics grew their employee count by 16% last year.
Obsidian Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | SVP, Program Planning & Development | Reveal Email/Phone |
4 | VP, Analytical Development | Reveal Email/Phone |
5 | VP, Clinical Operations & Translational Early Clinical Development | Reveal Email/Phone |
6 | VP IT and Facilities | Reveal Email/Phone |
7 | VP - Process Development and Manufacturing | Reveal Email/Phone |
8 | VP Regulatory Affairs | Reveal Email/Phone |
9 | SVP, Finance | Reveal Email/Phone |
10 | SVP, Business Development | Reveal Email/Phone |
Obsidian Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Obsidian Therapeutics?
Obsidian Therapeutics, founded in 2015, aspires to extend adoptive immunotherapy to every patient with cancer. We do this by building cell therapies with pharmacologic operating systems to provide treating physicians with precise and dynamic control of engineered cells in patients. We create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs. With this unique approach, we can dramatically improve on the current generation of cell therapies. Headquartered in Cambridge, MA, Obsidian has assembled an industry-leading team of experts in immunology, cell therapy, and oncology. We continue to build our team so please check our website (www.obsidiantx.com) often for job opportunities.
keywords:Healthcare,Human Resources Hr,Pharmaceuticals
$325M
Total Funding
124
Number of Employees
$19.2M
Revenue (est)
16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Obsidian Therapeutics News
Obsidian Therapeutics to Present Preclinical Data from cytoTIL15 Program at the American Associate of Cancer Research (AACR) Annual Meeting...
CAMBRIDGE, Mass., Sept. 9, 2021 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a $115 million Series B financing with a premier syndicate of life science investors led by The Column Group Crossover ...
Obsidian Therapeutics, Inc. announced that it has raised $115 million in a round of funding led by new investor TTCG Crossover Management, LLC on September 9, 2021. The transaction included participation form Vertex Pharmaceuticals Incorporated, new investors RA Capital Management, L.P, Citadel ...
Obsidian Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies, closed a $115m Series B financing. The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel co ...
CAMBRIDGE, Mass., July 25, 2019 /PRNewswire/ -- Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $17.2M | 124 | 5% | $120M |
#2 | $7.5M | 126 | 5% | N/A |
#3 | $22.7M | 126 | 47% | N/A |
#4 | $36.8M | 127 | 5% | N/A |
#5 | $21M | 127 | -2% | N/A |